Display options
Cite
Pi R, Liu Q, Takiff HE, et al. Fitness Cost and Compensatory Evolution in Levofloxacin-Resistant . Antimicrob Agents Chemother. 2020;64(8)doi: 10.1128/AAC.00224-20.
Pi, R., Liu, Q., Takiff, H. E., & Gao, Q. (2020). Fitness Cost and Compensatory Evolution in Levofloxacin-Resistant . Antimicrobial agents and chemotherapy, 64(8), . https://doi.org/10.1128/AAC.00224-20
Pi, Rui, et al. "Fitness Cost and Compensatory Evolution in Levofloxacin-Resistant ." Antimicrobial agents and chemotherapy vol. 64,8 (2020). doi: https://doi.org/10.1128/AAC.00224-20
Pi R, Liu Q, Takiff HE, Gao Q. Fitness Cost and Compensatory Evolution in Levofloxacin-Resistant . Antimicrob Agents Chemother. 2020 Jul 22;64(8). doi: 10.1128/AAC.00224-20. Print 2020 Jul 22. PMID: 32482677; PMCID: PMC7526816.
Copy Download .nbib Format: NLM
Share it on

Antimicrob Agents Chemother. 2020 Jul 22;64(8). doi: 10.1128/AAC.00224-20. Print 2020 Jul 22.

Fitness Cost and Compensatory Evolution in Levofloxacin-Resistant .

Antimicrobial agents and chemotherapy

Rui Pi, Qingyun Liu, Howard E Takiff, Qian Gao

Affiliations

  1. Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, School of Basic Medical Sciences, Shanghai Public Health Clinical Center Fudan University, Shanghai, China.
  2. Integrated Mycobacterial Pathogenomics Unit, Institut Pasteur, Paris, France.
  3. Department of Tuberculosis Control and Prevention, Shenzhen Nanshan Centre for Chronic Disease Control, Shenzhen, China.
  4. Instituto Venezolano de Investigaciones Cientificas, Caracas, Venezuela.
  5. Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, School of Basic Medical Sciences, Shanghai Public Health Clinical Center Fudan University, Shanghai, China [email protected].

PMID: 32482677 PMCID: PMC7526816 DOI: 10.1128/AAC.00224-20

Abstract

We isolated spontaneous levofloxacin-resistant strains of

Copyright © 2020 American Society for Microbiology.

Keywords: compensatory mutation; fitness cost; levofloxacin; mycobacteria; resistance

References

  1. Evol Appl. 2015 Mar;8(3):273-83 - PubMed
  2. Nat Genet. 2011 Dec 18;44(1):106-10 - PubMed
  3. Tuberculosis (Edinb). 2011 May;91(3):238-43 - PubMed
  4. Mol Biol (Mosk). 2017 Jul-Aug;51(4):595-602 - PubMed
  5. Microbiol Spectr. 2014 Aug;2(4):MGM2-0009-2013 - PubMed
  6. Evol Med Public Health. 2013 Jan;2013(1):65-74 - PubMed
  7. Rinsho Byori. 1988 Nov;36(11):1261-7 - PubMed
  8. Biosci Biotechnol Biochem. 2017 Jul;81(7):1343-1347 - PubMed
  9. PLoS One. 2019 Nov 20;14(11):e0218299 - PubMed
  10. FEMS Microbiol Rev. 2017 May 1;41(3):354-373 - PubMed
  11. Front Microbiol. 2016 Jun 02;7:830 - PubMed
  12. Elife. 2018 Oct 30;7: - PubMed
  13. Int J Antimicrob Agents. 2008 Feb;31(2):115-21 - PubMed
  14. J Antimicrob Chemother. 2017 Jul 1;72(7):1893-1900 - PubMed
  15. BMC Genomics. 2017 Jul 13;18(1):530 - PubMed

Substances

MeSH terms

Publication Types